NCT03893565 - Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

May 6, 2019

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions

Colitis, Ulcerative

Interventions

DRUG

GSK2831781 - Double Blind Phase

GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).

DRUG

Placebo

Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).

DRUG

GSK2831781 - Open Label phase

GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.

Trial Locations (61)

1612

GSK Investigational Site, Sofia

1619

GSK Investigational Site, Gauteng

6001

GSK Investigational Site, Port Elizabeth

9301

GSK Investigational Site, Bloemfontein

10065

GSK Investigational Site, New York

10117

GSK Investigational Site, Tallinn

10617

GSK Investigational Site, Tallinn

21009

GSK Investigational Site, Vinnytsia

21018

GSK Investigational Site, Vinnytsia

23000

GSK Investigational Site, Zrenjanin

31059

GSK Investigational Site, Toulouse

38043

GSK Investigational Site, Grenoble

42270

GSK Investigational Site, Saint-Priest-en-Jarez

54511

GSK Investigational Site, Vandœuvre-lès-Nancy

61037

GSK Investigational Site, Kharkiv

63600

GSK Investigational Site, Brno

65025

GSK Investigational Site, Odesa

69050

GSK Investigational Site, Zaporizhzhia

69065

GSK Investigational Site, Zaporizhzhya

77900

GSK Investigational Site, Olomouc

78229

GSK Investigational Site, San Antonio

79059

GSK Investigational Site, Lviv

91324

GSK Investigational Site, Northridge

92337

GSK Investigational Site, Rialto

141001

GSK Investigational Site, Ludhiana

195257

GSK Investigational Site, Saint Petersburg

197022

GSK Investigational Site, Saint Petersburg

221005

GSK Investigational Site, Varanasi

302001

GSK Investigational Site, Jaipur

360005

GSK Investigational Site, Rajkot

410053

GSK Investigational Site, Saratov

440010

GSK Investigational Site, Nagpur

443011

GSK Investigational Site, Samara

603126

GSK Investigational Site, Nizhny Novgorod

630005

GSK Investigational Site, Novosibirsk

660022

GSK Investigational Site, Krasnoyarsk

274 01

GSK Investigational Site, Slaný

06202

GSK Investigational Site, Nice

530-0011

GSK Investigational Site, Osaka

1105 AZ

GSK Investigational Site, Amsterdam

85-168

GSK Investigational Site, Bydgoszcz

82-300

GSK Investigational Site, Elblag

57-230

GSK Investigational Site, Kamieniec Ząbkowicki

40-659

GSK Investigational Site, Katowice

44-190

GSK Investigational Site, Knurów

31-009

GSK Investigational Site, Krakow

31-501

GSK Investigational Site, Krakow

90-302

GSK Investigational Site, Lodz

35-326

GSK Investigational Site, Rzeszów

81-756

GSK Investigational Site, Sopot

28-200

GSK Investigational Site, Staszów

87-100

GSK Investigational Site, Torun

03-340

GSK Investigational Site, Warsaw

50-449

GSK Investigational Site, Wroclaw

22-400

GSK Investigational Site, Zamość

080 01

GSK Investigational Site, Prešov

0002

GSK Investigational Site, Pretoria

02000

GSK Investigational Site, Kiev

CB2 0QQ

GSK Investigational Site, Cambridge

OX3 9DU

GSK Investigational Site, Headington

E11 1NR

GSK Investigational Site, London